Progress Made in Treating Stargardt’s and Dry AMD Using Embryonic Stem Cells
January 12, 2012
Advanced Cell Technology today announced updated information on their three clinical trials underway to treat Stargardt’s Macular Dystrophy (at UCLA’s Jules Stein Eye Institute and at Moorfield’s Eye Hospital) and to treat the dry form of AMD also at Jules Stein.
The first two patients have received embryonic stem cell derived retinal pigment epithelial cells (hESC-derived RPE) and the company has been authorized to treat the next two patients in the UCLA study, while the first patient will be treated in the UK study in the upcoming week(s), while additional patients will be treated at UCLA in the same time frame.
To read more about these groundbreaking studies please follow this link.
You might also enjoy...
- First Patients With Macular Degeneration and Stargardt’s Disease Receive Stem Cell Treatment
- First Clinical Results of Using Embryonic Stem Cells to Treat Eye Disease Published in The Lancet
- Using Stem Cells to Treat Dry AMD and Stargardt’s Macular Dystrophy
- ACT Adds Third Clinical Trial Site for Testing Treatment of Dry Macular Degeneration With Embryonic Stem Cells
- Can ACTC’s Stem Cells be Used to Treat Severe Myopia?
Jump down to form below to submit your own comments